Evidence mapPaperPMID 38908805Full record

ArticleJournal of vascular surgery2024

Surgery or endovascular therapy for patients with chronic limb-threatening ischemia requiring infrapopliteal interventions.

Kristina A Giles, Alik Farber, Matthew T Menard, Michael S Conte, Brian W Nolan, Jeffrey J Siracuse, Michael B Strong, Gheorghe Doros, Maarit Venermo, Ezana Azene and 2 more

Abstract readComparative Study
In one paragraph

Article in Journal of vascular surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Ultra-distal bypass remains a valuable option for tibial disease with tissue loss.Journal of vascular surgery cases and innovative techniques · 2026
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kristina A GilesDivision of Vascular and Endovascular Surgery, Maine Medical Center, Portland, ME. Electronic address: Kristina.Giles@MaineHealth.org.
Alik FarberDivision of Vascular and Endovascular Surgery, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA.
Matthew T MenardDivision of Vascular and Endovascular Surgery, Brigham and Woman's Hospital, Boston, MA.
Michael S ConteDivision of Vascular and Endovascular Surgery, University of California San Francisco.
Brian W NolanDivision of Vascular and Endovascular Surgery, Maine Medical Center, Portland, ME.
Jeffrey J SiracuseDivision of Vascular and Endovascular Surgery, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA.
Michael B StrongBrigham and Woman's Hospital, Boston, MA.
Gheorghe DorosDepartment of Biostatistics, Boston University, School of Public Health, Boston, MA.
Maarit VenermoDepartment of Vascular Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Ezana AzeneDepartment of Interventional Radiology, Gundersen Health System, La Crosse, WI.
Kenneth RosenfieldVascular Medicine and Intervention, Massachusetts General Hospital, Boston, MA.
Richard J PowellHeart and Vascular Center, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.

Funding

NHLBI NIH HHS U01 HL107352NHLBI NIH HHS U01 HL107407NHLBI NIH HHS U01 HL115662
6 · The paper itself

Abstract

objectiveThe recent publication of randomized trials comparing open bypass surgery to endovascular therapy in patients with chronic limb-threatening ischemia, namely, Best Endovascular vs Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) and Bypass versus Angioplasty in Severe Ischaemia of the Leg-2 (BASIL-2), has resulted in potentially contradictory findings. The trials differed significantly with respect to anatomical disease patterns and primary end points. We performed an analysis of patients in BEST-CLI with significant infrapopliteal disease undergoing open tibial bypass or endovascular tibial interventions to formulate a relevant comparator with the outcomes reported from BASIL-2.

methodsThe study population consisted of patients in BEST-CLI with adequate single segment saphenous vein conduit randomized to open bypass or endovascular intervention (cohort 1) who additionally had significant infrapopliteal disease and underwent tibial level intervention. The primary outcome was major adverse limb event (MALE) or all-cause death. MALE included any major limb amputation or major reintervention. Outcomes were evaluated using Cox proportional regression models.

resultsThe analyzed subgroup included a total of 665 patients with 326 in the open tibial bypass group and 339 in the tibial endovascular intervention group. The primary outcome of MALE or all-cause death at 3 years was significantly lower in the surgical group at 48.5% compared with 56.7% in the endovascular group (P = .0018). Mortality was similar between groups (35.5% open vs 35.8% endovascular; P = .94), whereas MALE events were lower in the surgical group (23.3% vs 35.0%; P<.0001). This difference included a lower rate of major reinterventions in the surgical group (10.9%) compared with the endovascular group (20.2%; P = .0006). Freedom from above ankle amputation or all-cause death was similar between treatment arms at 43.6% in the surgical group compared with 45.3% the endovascular group (P = .30); however, there were fewer above ankle amputations in the surgical group (13.5%) compared with the endovascular group (19.3%; P = .0205). Perioperative (30-day) death rates were similar between treatment groups (2.5% open vs 2.4% endovascular; P = .93), as was 30-day major adverse cardiovascular events (5.3% open vs 2.7% endovascular; P = .12).

conclusionsAmong patients with suitable single segment great saphenous vein who underwent infrapopliteal revascularization for chronic limb-threatening ischemia, open bypass surgery was associated with a lower incidence of MALE or death and fewer major amputation compared with endovascular intervention. Amputation-free survival was similar between the groups. Further investigations into differences in comorbidities, anatomical extent, and lesion complexity are needed to explain differences between the BEST-CLI and BASIL-2 reported outcomes.

Indexed as

Amputation, SurgicalChronic Limb-Threatening IschemiaEndovascular ProceduresLimb SalvagePeripheral Arterial DiseasePopliteal ArterySaphenous VeinAgedAged, 80 and overChronic DiseaseCritical IllnessFemaleHumansIschemiaKaplan-Meier EstimateMaleAmputation-free survivalBASIL-2BEST-CLIChronic limb-threatening ischemiaInfrapopliteal diseaseMajor adverse limb eventsTibial bypassTibial diseaseTibial endovascular intervention

Identifiers

PMID38908805
PMCPMC11633720

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.